MitoSense is Supporting Targeting Mitochondria 2024
MitoSense will be sponosring the the 15th WMS Annual Meeting, Targeting Mitochondria 2024, on October 29-31 at DoubleTree by Hilton Berlin Ku'damm, Berlin, Germany.
About MitoSense
MitoSense, Inc. is a research and development company in the field of securing development of treatments for neurodegenerative diseases. With exclusively licensed technology to replenish the mitochondria in humans using Mitochondria Organelle Transplantation (MOT™️), the company, through its U.S. based research partner is initially focusing its efforts on treating ALS. MOT™️ may impact research for patients with Alzheimer’s, Parkinson’s, Huntington’s and other neurodegenerative diseases, none of which have a cure.
What do they do?
MitoSense uses a proprietary (patent pending) technique to replenish mitochondria to treat ALS. The technique has the potential to treat a wide range of indications including Alzheimer’s, Parkinson’s, Huntington’s, Multiple Sclerosis and other neurodegenerative diseases. With experienced leadership in business, government, research, and medical, we have brought together a multidisciplinary team to help in the fight.
Talk at Targeting Mitochondria 2024:
Dr. Mark Kindy, CEO at MitoSense will be presenting a major talk during the meeting in Berlin: "Mitochondrial Transplantation Mediates Improved Cellular Energy Metabolism, Restoration of Mitochondrial Function and Prevention of Cell Death"
In his talk Dr. Kindy will cover:
- Isolation and characterization of mitochondria
- Application of mitochondrial transplantation
- Reversal of cellular dysfunction
- Restoration of energy metabolism
MitoSense Website:
